|
Market Cap (25-Jun) $125,067,280 (1,258th) |
Close (30-Jun) $0.007 |
Volume (30-Jun) 188,484 |
Shortsold (14-May) 14,985,846 (0.14%) (426th) |
|
52w High $0.85 |
52w Low $0.350 |
P/E 10.33 |
EPS -0.07 |
ATH released this announcement to the ASX on 7 January 2022, 8:21. The announcement is not marked as price sensitive, and is 5 page(s) in length and 1.06MB in size.
You can view all announcements from ATH and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATH was 0.001% short sold according to ASIC data. It was ranked the 636th most shorted stock on the ASX. It is now ranked as the 426th most shorted stock on the ASX with 0.138% of total shares short sold as of the latest reported data (14 May 2026).
| Other Recent Announcements from ATH | |
|---|---|
| Investor Presentation | 22 June 2023, 11:13 |
| ATH to present at MST Rare Diseases Rich Returns Forum | 21 June 2023, 9:52 |
| ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder | 30 May 2023, 13:32 |
| Change in substantial holding | 7 January 2022, 8:21 |
| New US Patent for Compounds to Treat Neurodegeneration | 6 January 2022, 10:15 |
| Alterity to present at H.C. Wainwright Conference | 5 January 2022, 10:33 |
| Final Director's Interest Notice x 2 | 5 January 2022, 10:14 |
You must be logged in to post a reply.
Alterity Therapeutics 